IL1B and COVID-19: It was revealed that P4 decreases the production of IL-1β, IL-6, TNFα, and IL-12, as well as the production of chemokines (e.g., monocyte chemoattractant protein-1 MCP-1/CCL2); moreover, due to its good tolerability and neuroprotective properties, P4 could be a very useful addition to established COVID-19 therapy [12].